A Study to Assess Safety and Efficacy of a Leishmania Vaccine to Prevent Post Kala Azar Dermal Leishmaniasis (PKDL)

Inclusion Criteria: The patient volunteer must be: * Aged 12 to 50 years on the day of screening * Have had VL and have been cured following a standard regimen of SSG / PM * Females must be unmarried, single, or widowed * Willing and able to give written informed consent * For adolescents aged 12 to 17 years on the day of screening written informed consent from a parent must be obtained. All Participants * Uncomplicated VL responsive to SSG / PM treatment * Have relatively normal blood values in the setting of VL, defined as hemoglobin \>5.0 g/dL, white blood cells \>1.0 x10(9)/L, platelets \>40 x10(9)/L, liver function tests \< x5 normal, Creatinine \<1.5 mg/dL * Available for the duration of the study * Without any other significant health problems as determined by medical history, physical examination, results of screening tests and the clinical judgment of a medically qualified Clinical Investigator * Negative for malaria on blood smear * Judged, in the opinion of a medically qualified Clinical Investigator, to be able and likely to comply with all study requirements as set out in the protocol * Negative for human immunodeficiency virus (HIV), Hepatitis B and Hepatitis C * For females only, willing to undergo urinary pregnancy tests on the day of screening, on the day of vaccination (prior to vaccination) and 3, 6, 9 and 12 months after vaccination. Exclusion Criteria: The volunteer may not enter the study if any of the following apply: * Has HIV/VL coinfection * H…